How Doctors Decide to Approve Mounjaro
In Singapore, Mounjaro is not a medicine that should be approved casually or based on preference alone. Tirzepatide is a prescription-only medicine, and doctors are expected to assess whether prescribing is clinically appropriate, safe, and properly documented. That decision may be made in a physical clinic or through licensed telehealth services, but the duty of care remains the same.
Key Takeaways
Mounjaro is a prescription-only medicine in Singapore.
Doctors decide whether to approve Mounjaro based on clinical suitability, not patient demand alone.
Telehealth prescribing is allowed in Singapore, but remote consultations must meet appropriate clinical and ethical standards comparable to in-person care.
Assessment usually includes weight-related risk, medical history, current medicines, contraindications, and whether follow-up can be done safely.
Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and in those with serious hypersensitivity to tirzepatide or its excipients.
Approval is only the start; doctors also need to plan monitoring, dose escalation, and review of side effects.
What doctors are actually deciding when they assess Mounjaro
When a doctor considers Mounjaro, the decision is broader than whether a patient wants help with appetite or weight. The doctor is deciding whether tirzepatide is medically appropriate for that individual, whether the expected benefit is reasonable, whether any contraindications or warning factors are present, and whether the patient can be followed safely after starting treatment. This is consistent with Singapore’s broader regulatory position that prescribing must rest on sound medical grounds and proper professional judgment.
In Singapore, HSA materials identify Mounjaro as a prescription-only medicine, and HSA’s benefit-risk report for the earlier approval states the registered indication was as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. That means a doctor’s prescribing decision should begin with indication, clinical context, and patient-specific risk, rather than a general request for treatment.
The first step is usually a clinical suitability review
Weight and metabolic risk are part of the discussion
In practice, doctors usually begin with a medical history and baseline health review. For patients seeking help with weight-related concerns, body mass index, waist-related risk, and obesity-related conditions often matter because they help establish the broader metabolic picture. Singapore HealthHub materials note that, for Asian populations, BMI above 23 indicates increased health risk, while BMI 27.5 and above indicates high risk for weight-related health problems. HealthHub also states that obesity among Singaporeans is generally defined from BMI 27.5 upward.
Doctors do not use BMI alone as a yes-or-no switch. They usually interpret it alongside conditions such as type 2 diabetes, hypertension, fatty liver risk, sleep-related symptoms, previous weight-management attempts, and the patient’s overall treatment goals. The point is to decide whether tirzepatide fits the medical picture rather than whether it is simply available. This is especially important in a supervised treatment pathway.
Current indication and clinical rationale matter
A responsible approval decision also depends on why the medicine is being prescribed. HSA’s published summary report for Mounjaro states the approved indication at that time was glycaemic control in adults with type 2 diabetes mellitus, while HSA’s later drug approval notices show additional tirzepatide presentations were subsequently registered in Singapore. For patients asking about Mounjaro in a broader weight-management context, the treating doctor still has to decide whether the intended use is clinically justified and appropriate under current local practice and product registration status.
What doctors review before approving Mounjaro
Medical history and contraindications
Before prescribing, doctors should screen for reasons Mounjaro should not be used. HSA’s benefit-risk summary lists the key contraindications: a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and known serious hypersensitivity to tirzepatide or its excipients.
The same prescribing materials also describe important warnings and precautions, including severe gastrointestinal adverse reactions, acute kidney injury related to dehydration risk, pancreatitis warnings, gallbladder disease concerns, and caution in people with significant gastrointestinal disease such as severe gastroparesis. A doctor deciding whether to approve treatment therefore has to ask more than “Are you overweight?” They must also ask whether treatment can be started safely.
Other medicines and glucose-lowering therapy
Doctors also review a patient’s current medication list. This matters because tirzepatide may interact with the broader diabetes treatment plan, especially where insulin or insulin secretagogues are involved and hypoglycaemia risk may need attention. Medication review is also part of safe telemedicine and documentation standards.
Ability to tolerate and follow treatment
Approving Mounjaro also means deciding whether the patient is likely to manage dose escalation, injection use, side-effect monitoring, and follow-up reviews. Prescribing information for tirzepatide describes stepwise dose escalation rather than immediate use of higher doses. That supports a doctor-led process in which tolerability is reviewed over time instead of assuming everyone should start and continue in the same way.
How telehealth fits into the approval process in Singapore
Telehealth can be part of the prescribing pathway, but it does not reduce the clinical standard expected of the doctor. Ministry of Health states that telemedicine providers must have doctors as licensed holders and that registered medical practitioners providing telemedicine must follow the Singapore Medical Council’s Ethical Code and Ethical Guidelines. MOH also states that telemedicine must be delivered appropriately and carefully.
MOH’s telehealth guidance further states that the standard of care expected of doctors providing telemedicine should be comparable to what patients would receive in a face-to-face consultation. In other words, a remote consultation is not supposed to be a shortcut around proper clinical evaluation. The doctor still needs enough information to make a sound decision.
This point became especially clear in MOH’s enforcement actions against MaNaDr Clinic. MOH said very short teleconsultations that nevertheless resulted in medication prescribing raised concerns about safety and quality of care, including whether medications were prescribed on sound medical grounds. Those actions are a useful reminder that telehealth prescribing in Singapore is allowed, but it must still be clinically appropriate, properly documented, and ethically defensible.
Why doctors may decline to approve Mounjaro
A doctor may decide not to approve Mounjaro for several reasons. The patient may have a contraindication, the indication may not be sufficiently clear, the gastrointestinal risk may be too high, the patient’s current medicines may make treatment more complex, or the consultation may not provide enough information to prescribe safely. In telehealth, another reason for non-approval may simply be that the doctor believes an in-person examination or further investigations are needed first.
Declining to prescribe is not necessarily a rejection of the patient’s concerns. It may reflect proper clinical caution. Singapore’s regulatory and ethical framework expects doctors to prescribe only when they can justify the decision medically and document it appropriately.
Approval usually comes with ongoing requirements
When doctors do approve Mounjaro, the process does not end at the first prescription. Follow-up matters because the patient may need review of side effects, hydration status, gastrointestinal tolerance, adherence, dose escalation, and treatment response. Prescribing information specifically highlights clinically important adverse effects and precautions that may require monitoring.
In practical terms, this means Mounjaro should be understood as part of an ongoing doctor-supervised treatment plan rather than a one-time transaction. That is true whether the consultation happens in a clinic or through licensed telehealth.
Takeaway
How doctors decide to approve Mounjaro is ultimately a question of medical appropriateness, not convenience. In Singapore, tirzepatide is prescription-only, telehealth remains subject to the same duty-of-care standards as in-person care, and approval depends on factors such as indication, metabolic risk, contraindications, medication review, and the ability to monitor treatment safely over time.
To understand how prescribing decisions, remote consultations, medical requirements, and supervised tirzepatide access connect within Singapore care pathways, you can refer to How Mounjaro Is Prescribed in Singapore: Clinics, Telehealth, and Medical Requirements.
FAQ
Is Mounjaro prescription-only in Singapore?
Yes. HSA lists tirzepatide as a prescription-only medicine in Singapore.
Can a telehealth doctor prescribe Mounjaro in Singapore?
Telehealth prescribing can be part of care, but Ministry of Health says telemedicine must meet appropriate safeguards and that the standard of care should be comparable to face-to-face consultation. Whether a doctor prescribes depends on whether a proper clinical assessment can be done safely.
What do doctors check before approving Mounjaro?
Doctors typically review the clinical reason for treatment, weight and metabolic risk context, medical history, current medicines, contraindications, warning factors, and whether follow-up can be done safely.
Can a doctor refuse to prescribe Mounjaro?
Yes. A doctor may decline if the medicine is not clinically appropriate, if safety concerns are present, or if the consultation does not provide enough information to prescribe responsibly.
Does telehealth make approval easier?
Not by rule. Ministry of Health’s position is that telemedicine does not lower the clinical standard; doctors are still expected to meet proper ethical and professional obligations when prescribing.